Clinical Trial

To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated May 23, 2024 (before its estimated June 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to evaluate the efficacy and safety of Disitamab Vedotin combined with Toripalimab sequential chemotherapy as in patients with HR-positive, HER2-low breast cancer
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-04-24; most recent amendment 2024-05-21.
Status change: Not Yet Recruiting → Recruiting 2024-05-21
Trial Details
NCT Number NCT06389006
Lead Sponsor RemeGen Co., Ltd.
Conditions Breast Cancer
Enrollment 79 participants
Start Date 2024-04-29
Primary Completion 2025-06-01 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-05-23